Lacotab Syrup contains lacosamide at a concentration of 15 mg/ml and is indicated for the adjunctive treatment of partial-onset seizures in patients with epilepsy. Lacosamide is an antiepileptic agent that selectively enhances slow inactivation of voltage-gated sodium channels, stabilizing hyperexcitable neuronal membranes and inhibiting repetitive neuronal firing. This mechanism contributes to the reduction of seizure frequency and severity. Lacotab Syrup is formulated for oral administration, allowing for flexible dosing in pediatric and adult populations who may require an alternative to tablet formulations. The syrup form facilitates accurate dose titration and improved compliance, particularly in patients with swallowing difficulties. It is important to initiate therapy at a low dose and titrate gradually to minimize adverse effects such as dizziness, headache, nausea, and fatigue. Lacotab Syrup should be used under strict medical supervision, with regular monitoring of clinical response and potential side effects. Caution is advised in patients with cardiac conduction abnormalities, as lacosamide may prolong the PR interval. Concomitant use with other central nervous system depressants may enhance sedative effects. Lacotab Syrup offers an effective and well-tolerated option for seizure management, contributing to improved quality of life in patients with epilepsy.